Micro RNA 146a gene variant / TNF-α / IL-6 / IL-1 β; A cross-link axis inbetween oxidative stress, endothelial dysfunction and neuro-inflammation in acute ischemic stroke and chronic schizophrenic patients

2020 ◽  
Vol 679 ◽  
pp. 108193 ◽  
Author(s):  
Rowida Raafat Ibrahim ◽  
Reham A. Amer ◽  
Abeer A. Abozeid ◽  
Radwa Mahmoud Elsharaby ◽  
Noha M. Shafik
Keyword(s):  
Oxidative Stress ◽  
Ischemic Stroke ◽  
Endothelial Dysfunction ◽  
Acute Ischemic Stroke ◽  
Micro Rna ◽  
Gene Variant ◽  
Cross Link ◽  
Tnf Α ◽  
Schizophrenic Patients ◽  
Neuro Inflammation

Endothelial dysfunction in acute ischemic stroke

2013 ◽  
Vol 333 ◽  
pp. e242 ◽  
Author(s):  
M. Azhermacheva ◽  
K. Burkova ◽  
D. Plotnikov ◽  
V. Alifirova ◽  
M. Solovtsov
Keyword(s):  
Ischemic Stroke ◽  
Endothelial Dysfunction ◽  
Acute Ischemic Stroke

scholarly journals Adjunctive cytoprotective therapies in acute ischemic stroke: a systematic review

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
I. A. Mulder ◽  
E. T. van Bavel ◽  
H. E. de Vries ◽  
J. M. Coutinho
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Nitrosative Stress ◽  
Vasogenic Edema ◽  
Treatment Strategies ◽  
Oxidative And Nitrosative Stress ◽  
Main Trial ◽  
Safety Issues ◽  
Favourable Safety Profile ◽  
Neuro Inflammation

AbstractWith the introduction of endovascular thrombectomy (EVT), a new era for treatment of acute ischemic stroke (AIS) has arrived. However, despite the much larger recanalization rate as compared to thrombolysis alone, final outcome remains far from ideal. This raises the question if some of the previously tested neuroprotective drugs warrant re-evaluation, since these compounds were all tested in studies where large-vessel recanalization was rarely achieved in the acute phase. This review provides an overview of compounds tested in clinical AIS trials and gives insight into which of these drugs warrant a re-evaluation as an add-on therapy for AIS in the era of EVT. A literature search was performed using the search terms “ischemic stroke brain” in title/abstract, and additional filters. After exclusion of papers using pre-defined selection criteria, a total of 89 trials were eligible for review which reported on 56 unique compounds. Trial compounds were divided into 6 categories based on their perceived mode of action: systemic haemodynamics, excitotoxicity, neuro-inflammation, blood–brain barrier and vasogenic edema, oxidative and nitrosative stress, neurogenesis/-regeneration and -recovery. Main trial outcomes and safety issues are summarized and promising compounds for re-evaluation are highlighted. Looking at group effect, drugs intervening with oxidative and nitrosative stress and neurogenesis/-regeneration and -recovery appear to have a favourable safety profile and show the most promising results regarding efficacy. Finally, possible theories behind individual and group effects are discussed and recommendation for promising treatment strategies are described.

Variation of some oxidative stress and inflammatory markers in acute ischemic stroke

2013 ◽  
Vol 333 ◽  
pp. e208-e209
Author(s):  
I. Varga ◽  
D.I. Minea ◽  
I. Ionescu ◽  
R.M. Lupu ◽  
A. Dinu ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Inflammatory Markers

scholarly journals Evaluating the Role of Oxidative Stress in Acute Ischemic Stroke

2020 ◽  
Vol 11 (01) ◽  
pp. 156-159
Author(s):  
Bindu Menon ◽  
Krishnan Ramalingam ◽  
Rajeev Kumar
Keyword(s):  
Oxidative Stress ◽  
Ischemic Stroke ◽  
Acute Stroke ◽  
Acute Ischemic Stroke ◽  
Lipid Membranes ◽  
Demographic Data ◽  
Stroke Severity ◽  
Stroke Patients ◽  
Antioxidant Power

Abstract Background The role of oxidative stress in neuronal injury due to ischemic stroke has been an interesting topic in stroke research. Malondialdehyde (MDA) has emerged as a sensitive oxidative stress biomarker owing to its ability to react with the lipid membranes. Total antioxidant power (TAP) is another biomarker to estimate the total oxidative stress in stroke patients. We aimed to determine the oxidative stress in acute stroke patients by measuring MDA and TAP. Materials and Methods MDA and TAP were determined in 100 patients with ischemic stroke and compared with that in 100 age- and sex-matched healthy adults. Demographic data, stroke severity measured by the National Institutes of Health Stroke Scale (NIHSS), and disability measured by the Barthel index (BI) were recorded. The association of MDA and TAP with other variables was analyzed by paired t-test. Results Of the whole sample, 74% represented males. The mean NIHSS score was 13.11 and BI was 38.87. MDA was significantly higher in stroke patients (7.11 ± 1.67) than in controls (1.64 ± 0.82; p = 0.00). TAP was significantly lower in stroke patients (5.72 ± 1.41) than in controls (8.53 ± 2.4; p = 0.00). The lipid profile and blood sugar levels were also significantly higher in stroke patients. There was no association of MDA and TAP with other variables. Conclusion We found that oxidative stress was associated with acute ischemic stroke. However, we could not establish an association between oxidative stress and the severity of acute stroke.

scholarly journals Efficacy of High-Dose and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcomes in Patient with Acute Ischemic Stroke: A Randomized, Double-Blind, Parallel, Controlled Trial

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Nattaphol Uransilp ◽  
Pannawat Chaiyawatthanananthn ◽  
Sombat Muengtaweepongsa
Keyword(s):  
Oxidative Stress ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Barthel Index ◽  
Low Dose ◽  
Past History ◽  
High Dose ◽  
Neurological Outcomes ◽  
History Of ◽  
Vascular Oxidative Stress

Backgrounds. Stroke is the leading cause of death and long-term disability. Oxidative stress is elevated during occurrence of acute ischemic stroke (AIS). Soluble LOX-1 (sLOX-1) and NO are used as biomarkers for vascular oxidative stress that can reflect stabilization of atherosclerotic plaque. Previous study showed that simvastatin can reduce oxidative stress and LOX-1 expression. Objectives. To evaluate neurological outcomes and serum sLOX-1 and NO levels in patients with AIS treatment with low dose 10 mg/day and high dose 40 mg/day of simvastatin. Methods. 65 patients with AIS within 24 hours after onset were randomized to treatment with simvastatin 10 mg/day or 40 mg/day for 90 days. Personal data and past history of all patients were recorded at baseline. The blood chemistries were measured by standard laboratory techniques. Serum sLOX-1 and NO levels and neurological outcomes including NIHSS, mRS, and Barthel index were tested at baseline and Day 90 after simvastatin therapy. Results. Baseline characteristics were not significantly different in both groups except history of hypertension. Serum sLOX-1 and NO levels significantly reduce in both groups (sLOX-1 = 1.19±0.47 and 0.98±0.37 ng/ml; NO = 49.28±7.21 and 46.59±9.36 μmol/l) in 10 mg/day and 40 mg/day simvastatin groups, respectively. Neurological outcomes including NIHSS, mRS, and Barthel index significantly improve in both groups. However, no difference in NO level and neurological outcomes was found at 90 days after treatment as compared between low dose 10 mg/day and high dose 40 mg/day of simvastatin. Conclusion. High-dose simvastatin might be helpful to reduce serum sLOX-1. But no difference in clinical outcomes was found between high- and low-dose simvastatin. Further more intensive clinical trial is needed to confirm the appropriate dosage of simvastatin in patients with acute ischemic stroke. This trial is registered with ClinicalTrials.gov ID: NCT03402204.

scholarly journals The Risk of Albuminuria to The Ischemic Acute Patient With or Without Metabolic Syndrome

2019 ◽  
Vol 2 (3) ◽  
pp. 128-132
Author(s):  
Ana Fresia ◽  
Yuneldi Anwar
Keyword(s):  
Metabolic Syndrome ◽  
Ischemic Stroke ◽  
Endothelial Dysfunction ◽  
Cerebrovascular Disease ◽  
Acute Ischemic Stroke ◽  
Cause Of Death ◽  
Cerebrovascular Event ◽  
Increased Risk ◽  
Acute Patient

Stroke is not only a major cause of death, but also a leading cause of disability worldwide. Metabolic syndrome is one of the predictor of stroke since it has been linked to the development of atherosclerosis that will lead to cerebrovascular event. Albuminuria is known to be an indicator of endothelial dysfunction that is a major cause of cerebrovascular disease. In this study, 50 subjects of acute ischemic stroke consist of 25 subjects of acute ischemic stroke with metabolic syndrome and 25 subjects of acute ischemic stroke without metabolic syndrome. The ischemic stroke with metabolic syndrome population is significantly associated with increased risk of albuminuria 16 times higher than the ischemic stroke without metabolic syndrome (OR = 16, IK95% 1.855 – 137.97, p=0.002).Subjects of ischemic stroke with metabolic syndrome is significantly associated with increased risk of albuminuria.

Sign in / Sign up

Export Citation Format

Share Document